Figure 5.
CUF37-2a protects against VEEV disease when administered 24h prior to challenge. In three independent experiments, Balb/c mice (7-8mice/group) remained untreated or were injected with CUF37-2a (5, 50 or 100 μg) intraperitoneally. 100LD50 VEEV strain TrD were administered subcutaneously 24h later. After challenge, mice were observed twice daily for clinical signs of infection and were culled when appropriate using humane endpoints. *P = 0.0043, **P = 0.0001 and ***P < 0.0001, Mantel-Maenszel Logrank test.